Canada markets close in 4 hours 6 minutes

Scopus BioPharma Inc. (SCPS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00110.0000 (0.00%)
As of 11:38AM EDT. Market open.
Currency in USD

Valuation Measures4

Market Cap (intraday) 46.29k
Enterprise Value -315.81k
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.42
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA 0.03

Trading Information

Stock Price History

Beta (5Y Monthly) 1.01
52-Week Change 3-97.80%
S&P500 52-Week Change 324.19%
52 Week High 30.1050
52 Week Low 30.0002
50-Day Moving Average 30.0019
200-Day Moving Average 30.0304

Share Statistics

Avg Vol (3 month) 31.35k
Avg Vol (10 day) 3837
Shares Outstanding 542.08M
Implied Shares Outstanding 642.08M
Float 834.22M
% Held by Insiders 118.69%
% Held by Institutions 10.00%
Shares Short (Nov 30, 2022) 423.77k
Short Ratio (Nov 30, 2022) 40.22
Short % of Float (Nov 30, 2022) 40.25%
Short % of Shares Outstanding (Nov 30, 2022) 40.11%
Shares Short (prior month Oct 31, 2022) 419.47k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2022
Most Recent Quarter (mrq)Jun 30, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-538.06%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -9.34M
Net Income Avi to Common (ttm)-8.7M
Diluted EPS (ttm)-0.3100
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)362.1k
Total Cash Per Share (mrq)0.01
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.05
Book Value Per Share (mrq)-0.24

Cash Flow Statement

Operating Cash Flow (ttm)-3.04M
Levered Free Cash Flow (ttm)490.41k